Investigator: Sara Bringhen

Medical centers

Trials

A multicenter, open label phase II study of isatuximab, ixazomib and low dose dexamethasone in a cohort of intermediate fit and in a cohort of frail newly diagnosed multiple myeloma (MM) patients.
CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE III TRIAL.